Thermo Fisher Scientific Inc. (TMO) Shares Sold by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,064 shares of the medical research company’s stock after selling 16,105 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Thermo Fisher Scientific were worth $32,478,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Pitcairn Co. grew its position in shares of Thermo Fisher Scientific by 1.3% during the 2nd quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock worth $3,495,000 after purchasing an additional 215 shares in the last quarter. Hall Capital Management Co. Inc. grew its position in shares of Thermo Fisher Scientific by 6.2% during the 3rd quarter. Hall Capital Management Co. Inc. now owns 3,780 shares of the medical research company’s stock worth $923,000 after purchasing an additional 220 shares in the last quarter. Nvwm LLC grew its position in shares of Thermo Fisher Scientific by 6.1% during the 2nd quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock worth $877,000 after purchasing an additional 242 shares in the last quarter. Tiedemann Advisors LLC grew its position in shares of Thermo Fisher Scientific by 19.4% during the 2nd quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock worth $315,000 after purchasing an additional 247 shares in the last quarter. Finally, Chesapeake Wealth Management grew its position in shares of Thermo Fisher Scientific by 6.0% during the 2nd quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock worth $910,000 after purchasing an additional 249 shares in the last quarter. 85.47% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director Tyler Jacks sold 4,772 shares of the stock in a transaction that occurred on Monday, November 19th. The shares were sold at an average price of $239.75, for a total transaction of $1,144,087.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Gregory J. Herrema sold 17,235 shares of the stock in a transaction that occurred on Thursday, November 29th. The stock was sold at an average price of $247.00, for a total transaction of $4,257,045.00. Following the sale, the insider now owns 26,446 shares in the company, valued at approximately $6,532,162. The disclosure for this sale can be found here. Insiders have sold a total of 147,527 shares of company stock worth $36,467,332 in the last quarter. 0.49% of the stock is currently owned by company insiders.

NYSE TMO opened at $249.55 on Monday. The company has a current ratio of 1.84, a quick ratio of 1.27 and a debt-to-equity ratio of 0.66. The company has a market cap of $100.46 billion, a P/E ratio of 26.30, a PEG ratio of 1.81 and a beta of 1.08. Thermo Fisher Scientific Inc. has a 1 year low of $181.51 and a 1 year high of $250.75.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. The business had revenue of $5.92 billion for the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the business posted $2.31 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 11.04 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a share repurchase plan on Friday, September 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2.1% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, January 15th. Investors of record on Monday, December 17th will be given a dividend of $0.17 per share. The ex-dividend date is Friday, December 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is 7.17%.

A number of brokerages have issued reports on TMO. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Friday. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $254.00 to $260.00 and gave the stock an “overweight” rating in a research report on Thursday, October 25th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $256.00 to $264.00 and gave the stock an “outperform” rating in a research report on Thursday, October 25th. Cleveland Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Thursday, October 18th. Finally, Citigroup increased their target price on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, October 10th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $263.45.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/12/03/thermo-fisher-scientific-inc-tmo-shares-sold-by-british-columbia-investment-management-corp.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: What is a Leveraged Buyout (LBO)?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit